Biomarin Pharmaceutical: Q3 Earnings Insights

Biomarin Pharmaceutical BMRN reported its Q3 earnings results on Wednesday, October 26, 2022 at 04:03 PM.

Here's what investors need to know about the announcement.

Biomarin Pharmaceutical missed estimated earnings by 300.0%, reporting an EPS of $-0.04 versus an estimate of $-0.01.

Revenue was up $96.60 million from the same period last year.

Last quarter the company beat on EPS by $0.48 which was followed by a 5.18% increase in the share price the next day.

Here's a look at Biomarin Pharmaceutical's past performance:

Quarter	Q2 2022	Q1 2022	Q4 2021	Q3 2021
EPS Estimate	0.11		-0.32	-0.25
EPS Actual	0.59	0.17	-0.32	-0.20
Revenue Estimate	521.47M	507.52M	442.39M	435.32M
Revenue Actual	533.80M	519.36M	449.81M	408.74M

To track all earnings releases for Biomarin Pharmaceutical visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Calendar